Pharmaceutical Executive
Three key questions dominate the agency’s Breakthrough Therapy Designation program since its 2012 launch.
Christopher-Paul Milne
Advertisement
Articles by Christopher-Paul Milne
Pharmaceutical Executive
The US drug regulatory system fails to address the country’s most urgent medical needs with the resources appropriate for the task. But change is possible.
Advertisement
Latest Updated Articles
Meeting Unmet Medical Needs: The Disparity DilemmaFebruary 1st 2015
FDA’s Breakthrough Therapy DesignationSeptember 8th 2015
Advertisement
Advertisement
Trending on PharmExec
1
TrumpRx Selling Medicines at Higher Prices Than Other Countries: Report
2
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
3
Pharmaceutical Executive Daily: Analysis on TrumpRx List Pricing
4
What Are the ‘Last Mile Issues’ Impacting Pharma?
5